US 9,096,651

Application 12/679,922 · Granted Aug 4, 2015

Method of modifying isoelectric point of antibody via amino acid substitution in cdr

Estimated expiration

February 15, 2030

3y 86d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTJP2008067534: Resource not found (404)
Earliest effective filing
Sep 26, 2008
+ 20 years
Sep 26, 2028
PTA +507d
Feb 15, 2030
No TD
—
Final
Feb 15, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
October 1, 2010
Earliest effective filing
September 26, 2008
Issue date
August 4, 2015
PTA
+507 days
Base expiry (before PTA)
September 26, 2028

September 26, 2008 + 20 years = September 26, 2028 + 507 PTA days = February 15, 2030

  • National stage entry of application PCTJP2008067534, filed Sep 26, 2008

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 12/679,922 · US 9,096,651

PatentReply compiles the prosecution history behind US 9,096,651: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9096651

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.